Immix Biopharma (IMMX) Corporate presentation summary

Unmet need in relapsed/refractory AL amyloidosis

• Approximately 38,500 U.S. patients suffer from relapsed/refractory AL amyloidosis with no FDA-approved therapies, facing poor outcomes and limited treatment options.

• Current standard of care yields only a 0-10% complete response rate, with most patients requiring second-line therapy within a year.

• Existing therapies are largely ineffective after relapse, and off-label drug use is common but unsatisfactory.

NXC-201: Mechanism and clinical innovation

• NXC-201 is a BCMA-targeted CAR-T therapy designed to eliminate dysfunctional plasma cells producing toxic light chains.

• Proprietary construct optimizations reduce non-specific activation and cytokine release, enhancing safety and efficacy.

• NXC-201 aims to intervene early, preventing organ failure and improving patient quality of life.

Clinical trial results and efficacy

• NEXICART-1 (ex-US) and NEXICART-2 (US) trials show a 75% complete response rate in relapsed/refractory AL amyloidosis, far surpassing current standards.

• Rapid normalization of disease markers and organ responses observed within the first month of treatment.

• Four additional patients in the US trial have normalized disease markers, predicting future complete responses.